Phaseline

Companies › Suzhou Alphamab

Suzhou Alphamab: clinical trials, targets and expected readouts

3 active drug programs in 7 registered trials: 3 Phase 1, 3 Phase 3, 1 Phase 2; Cardiovascular, Genitourinary, Other, Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KN057
Tissue factor pathway inhibitor (TFPI) analog
–Phase 3Hemophilia A With Inhibitor; Hemophilia A Without Inhibitor; Hemophilia A or BDec 2026
KN060
Factor XI inhibitor
F11Phase 2Knee Arthroplasty, Total; Hypertension; End-Stage Renal Disease Requiring HaemodialysisDec 2026
KN069–Phase 1Overweight or ObesityApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06312475KN057Phase 3Hemophilia A With InhibitorHematologyOct 2025
NCT06180889KN060Phase 2Knee Arthroplasty, TotalOtherDec 2025
NCT06569108KN057Phase 3Hemophilia A Without InhibitorHematologyDec 2026
NCT07191899KN060Phase 1HypertensionCardiovascularDec 2026
NCT06547775KN069Phase 1Overweight or ObesityMetabolic and endocrineApr 2027
NCT07201467KN060Phase 1End-Stage Renal Disease Requiring HaemodialysisGenitourinaryAug 2027
NCT07545395KN057Phase 3Hemophilia A or BHematologyDec 2027

Targets

F11 (1)

Companies with the same targets

Regeneron Pharmaceuticals Anthos Therapeutics Johnson & Johnson (Janssen) Sirnaomics

Companies built like this

Shenzhen Salubris Pharmaceuticals JW Pharmaceutical Beijing QL Biopharmaceutical ScinnoHub Pharmaceutical Shanghai Minwei Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.